Lilly Reports Solid First-Quart...( Company delivers dou...)

Company delivers double-digit sales growth

INDIANAPOLIS, April 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2008.

Financial results are presented on both a reported and a pro forma basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all sales and expenses recognized by the company during the period. Pro forma results assume the ICOS acquisition was completed January 1, 2007.

First-Quarter Highlights -- Reported Results

-- Sales increased 14 percent, to $4.808 billion.

-- Products launched this decade -- Alimta(R), Byetta(R), Cialis(R),

Cymbalta(R), Forteo(R), Strattera(R), Symbyax(R), Xigris(R) and

Yentreve(R) -- collectively grew 33 percent, to $1.678 billion, and

accounted for 35 percent of total sales, compared with 30 percent of

total sales in the first quarter of 2007.

-- Net income and earnings per share grew to $1.064 billion and $.97,

respectively, compared with first-quarter 2007 net income of $508.7

million and earnings per share of $.47.

First-Quarter Highlights -- Pro Forma Results

-- Sales increased 12 percent, to $4.808 billion.

-- Sales of products launched this decade collectively grew 26 percent and

represented 35 percent of total sales.

Product Sales Highlights

------------------------

% Change

(Dollars in millions) First Quarter Over/(Under)

2008 2007 2007

---------- -----
'/>"/>